Abstract
During the COVID-19 pandemic, the monitoring of SARS-COV-2 RNA in wastewater was used to track the evolution and emergence of variant lineages and gauge infection levels in the community, informing appropriate public health responses without relying solely on clinical testing. As more sublineages were discovered, it increased the difficulty in identifying distinct variants in a mixed population sample, particularly those without a known lineage. Here, we compare two next-generation sequencing technologies, Illumina and Nanopore, in order to determine their efficacy at detecting variants of differing abundance, using 248 wastewater samples from various Quebec and Ontario cities. Our study used two analytical approaches to identify main variants in the samples: the presence of signature and marker mutations, and the co-occurrence of signature mutations within the same amplicon. We observed that each sequencing method detected certain variants at different frequencies as each method preferentially detects mutations of distinct variants. Illumina sequencing detected more mutations with a predominant lineage that is in low abundance across the population or unknown for that time period, while Nanopore sequencing had a higher detection rate of mutations that are predominantly found in the high abundance B.1.1.7 (Alpha) lineage as well as a higher sequencing rate of co-occurring mutations in the same amplicon. We present a workflow that integrates short read and long read sequencing to improve the detection of SARS-CoV-2 variant lineages in mixed population samples, such as wastewater.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was supported by the Coronavirus Variants Rapid Response Network (CoVaRR-Net). CoVaRR-Net is funded by an operating grant from the Canadian Institutes of Health Research (CIHR) - Instituts de recherche en sante du Canada (FRN# 175622). Wastewater sampling in Quebec was supported by the Fond de la Recherche du Quebec - Nature et Technologie (COVID-19 Projets speciaux - Eaux usees), the Trottier Family Foundation, and the Molson Foundation. Further support of the work was provided by the Canada Foundation of Innovation Special opportunities grant #41012 to J.R. and by the Canada Foundation for Innovation grants CFI 33406 and CFI-MSI 35444 to J.R.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
↵† J.R. and T.P.S. jointly supervised this work
Data Availability
Raw sequencing data presented in the study are openly available in the NCBI database under BioProject ID PRJNA1127571 (https://www.ncbi.nlm.nih.gov/bioproject/1127571).
